NervGen Pharma (NASDAQ:NGEN) Receives $18.00 Consensus Target Price from Analysts

Shares of NervGen Pharma (NASDAQ:NGEN) have been assigned an average recommendation of “Moderate Buy” from the five analysts that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, one has issued a buy rating and two have given a strong buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $18.00.

Several equities analysts recently weighed in on the company. Zacks Research raised NervGen Pharma to a “hold” rating in a research note on Wednesday, April 29th. TD Cowen assumed coverage on NervGen Pharma in a research note on Thursday, June 11th. They set a “buy” rating on the stock. Stifel Nicolaus raised NervGen Pharma to a “strong-buy” rating in a research note on Thursday, April 23rd. Weiss Ratings assumed coverage on NervGen Pharma in a research note on Friday, April 24th. They set a “sell (d-)” rating on the stock. Finally, Wall Street Zen raised NervGen Pharma from a “sell” rating to a “hold” rating in a research note on Friday, May 29th.

NervGen Pharma Stock Up 9.5%

NervGen Pharma stock opened at $2.19 on Thursday. NervGen Pharma has a twelve month low of $1.70 and a twelve month high of $6.30. The company has a market cap of $176.58 million and a price-to-earnings ratio of -24.33.

NervGen Pharma (NASDAQ:NGEN) last posted its quarterly earnings results on Friday, May 15th. The company reported $999.00 EPS for the quarter, beating the consensus estimate of ($0.07) by $999.07.

NervGen Pharma Company Profile

NervGen Pharma Corp. is a clinical-stage biotechnology company focused on developing therapies to promote nerve repair and restore neurological function following injury or disease. The company advances regenerative approaches intended to address damage in the central and peripheral nervous systems, pursuing programs that aim to translate preclinical repair concepts into human treatments.

The company’s lead investigational candidate is NVG-291, which is being evaluated in clinical studies for indications that include spinal cord injury, neuropathic conditions and neurodegenerative disease settings.